Justice Ketanji Brown Jackson asked Erin Hawley, the attorney for Alliance Defending Freedom -- the group representing the plaintiffs -- if a nationwide reversal of the FDA's approval of mifepristone is needed and if the court can simply rule that doctors do not need to prescribe the pill if they have conscience objections.

"Do we have to entertain your argument that no one in the world can have this drug in order to protect your client?" the justice asked.

Hawley argued that given the "emergency nature," it is "impracticable" to not have a broader ban or block on access to the pill.

Justice Neil Gorsuch echoed Jackson's question and asked if it is enough for the court to rule on behalf of the plaintiffs not being required to prescribe the pill and why the court has to consider a universal injunction.

Two-thirds of Americans (66%) said mifepristone should remain on the market in an ABC News/Washington Post poll conducted last year.

Plus, 72% of Americans said at the time that access to the drug should remain the same.

Overall, 78% of Americans said the decision whether to have an abortion should be left to a woman and her doctor rather than regulated by law. That view was shared by 58% of Republicans.

The poll (conducted 10 months after the fall of Roe) also found half of Americans thought the Supreme Court justices base their rulings mainly on their personal political opinions, not on the law. Before the abortion ruling, the public was divided 46%-45% on whether the justices' rulings were based mainly on the law or on their own political preferences.

Attorney Erin Hawley, representing the anti-abortion Alliance for Hippocratic Medicine that is challenging mifepristone, has begun her presentation to the justices.

Hawley is echoing the alliance's attacks on the drug's use and regulation by the FDA, contending that it creates harm to women and burdens doctors who must then care for such patients who use mifepristone.

Hawley also invoked an "intolerable" choice that is created by the widespread use of mifepristone -- if an anti-abortion doctor must consider treating abortion patients in an emergency situation or not.

-ABC News' Adam Carlson

Jessica Ellsworth, the attorney for Danco Labs, was asked by Justice Ketanji Brown Jackson if she was concerned about the prospect of judges parsing medical and scientific studies without specialized knowledge.

"I think we have significant concerns about that," Ellsworth said, noting the pharmaceutical industry submitted briefs to the court expressing that worry.

She went on to state that U.S. District Judge Matthew Kacsmaryk, who initially ruled to suspend mifepristone's approval, relied on studies that "were not in the administrative record" and never would have been.

"They have since been retracted for lack of scientific rigor and misleading presentations of data," she said.

Sage Publishing said it issued the retractions from the journal Health Services Research and Managerial Epidemiology because of methodology issues and conflicts of interest, ABC News previously reported.

Medication abortion quickly became the target of multiple lawsuits after the Supreme Court struck down Roe's guarantees to national abortion access.

Last year, U.S. District Judge Matthew Kacsmaryk in Texas issued an unprecedented ruling suspending the FDA's initial approval of the drug (which has been on the market for nearly 25 years) because, he said, the drug was unsafe and its approval process rushed.

Kacsmaryk's order was partially blocked by the 5th U.S. Circuit Court of Appeals, though that court held the FDA acted unlawfully when it eased rules in 2016 and 2021 to allow the pill to be mailed to patients, prescribed by a medical professional and taken later in pregnancy.

The Biden administration then appealed to the U.S. Supreme Court, warning the loss of access would be "damaging for women and healthcare providers" nationwide and defending the FDA's process as supported by science and decades of safe use.